The Duchenne Muscular Dystrophy (DMD) treatment market is estimated to be valued at US$981.367 million in 2018 and is expected grow steadily during the forecast period. Duchenne Muscular Dystrophy (DMD) is a rare genetic disorder caused by the mutation of the DMD gene, which is responsible for making a protein called dystrophin causing progressive muscle degeneration. At present, there is no cure for the disease, certain research strategies are being worked upon, however, the treatment is prov Read more...
The IgA nephropathy disease treatment market is projected to grow at a CAGR of XX.XX% to reach US$XX.XXX billion by 2023, from US$XX.XXX billion in 2017. The rising number of cases diagnosed with kidney diseases every year is one of the major drivers driving the growth of the global IgA nephropathy disease treatment market during the forecast period. The United States from the North American region is expected to hold a major market share. The disease is one of the main causes of acute nephri Read more...
The gaucher disease treatment market is estimated to be valued at US$1,673.076 million and is projected to grow at a healthy rate during the forecast period. Gaucher’s disease is a genetic disease leading to fatty substances (sphingolipids) accumulation in cells and certain organs. The disease is caused by a hereditary deficiency of the enzyme beta-glucocerebrosidase (GCase). In the case of the defective enzyme, glucosylceramide can collect in the spleen, liver, kidneys, lungs, brain, an Read more...
The eosinophilic esophagitis (EoE) disease treatment market is projected to grow at a CAGR of XX.XX% to reach US$XX.XXX billion by 2023, from US$XX.XXX billion in 2017. Eosinophilic esophagitis (EOE) is a chronic allergic or immune condition where a person suffering with EOE tends to have inflammation of the esophagus. Esophagus is also known as food pipe which carries food from the mouth to the stomach. In the diseased state, a large number of white blood cells (WBCs) called eosinophils foun Read more...
The alcohol use disorder treatment market is estimated to grow by US$6.750 billion in 2018. The growing demand for the alcohol use disorder treatment is mainly attributed to the prevalence of this disease worldwide, with the high prevalence reported in Eastern European countries, parts of South East Asia and selected countries in Americas. According to the estimates by the Institute of Medicine, in 1996 the prevalence of Fetal Alcohol Syndrome (FAS) in the United States was between 0.5 and 3.0 Read more...
The acute kidney injury (AKI) disease treatment market is projected to grow at a CAGR of 1.10% to reach US$31.287 billion by 2024, from US$29.298 billion in 2018. The major drivers driving the growth of the global acute kidney injury (AKI) disease treatment market include growing elderly population, the prevalence of chronic diseases, and a growing number of acute care admissions and emergency department admissions leading to ICU admission. North America and Europe are expected to hold a signi Read more...
The merkel cell carcinoma disease treatment market was valued at US$2.914 billion in 2018 and is anticipated to grow at a CAGR of 3.13% to reach a market size of US$3.506 billion by 2024.. The presence of the Merkel cells can be found in the touch-sensitive area of the epidermis, which is also known as the outermost layer of the skin. Merkel cell carcinoma is considered to be an aggressive form of skin cancer which metastasizes very fast to other areas of the body. There are several drugs are Read more...
The hemochromatosis (iron overload) disease treatment market is projected to grow at a CAGR of XX.XX% to reach US$XX.XXX billion by 2023, from US$XX.XXX billion in 2017. Hemochromatosis disease is caused due to iron overload where there is an excessive iron build up in the body. It is either inherited or is acquired known as primary and secondary hemochromatosis. North America is expected to hold a significant market share as hemochromatosis is the most common genetic disorder in this region, Read more...
The global idiopathic pulmonary fibrosis treatment market is expected to reach US$4.020 billion by 2024 from US$2.090 billion in 2018, at a CAGR of 11.52%. Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic, progressive fibrosing interstitial pneumonia characterized by the formation of scar tissue within the lungs in the absence of any known cause. The scarring typically starts at the edges of the lungs and advances towards the center of the lungs. As the normal lung tissue is rep Read more...
Idiopathic pulmonary fibrosis (IPF) is an irreversible lung disease, in which the cells in the lung tissue surrounding the air sacs begin to die, as a result of which oxygen entering the bloodstream reduces, causing functional damage. Risk factors for the disease include smoking, exposure to certain types of dust, viral infection, gastroesophageal reflux disease and environmental concerns such as pollution. Since the disease is fatal, a lung transplant is a sought after treatment option while ce Read more...
.jpg)
